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Abstract
Background: To investigate intravitreal treatment efficiencies in patients suffering from exudative ARMD with a
BCVA≤ 0.05.
Methods: Retrospective analysis: Analysis parameters were lesion type, BCVA at baseline and at follow-up, the
intravitreal drug used, and its application frequency. Patients were divided into: 1) following injections of
bevacizumab, triamcinolone, their combination, or ranibizumab regardless of their lesion subtype, 2) or by lesion
subtype. Statistical tests were performed using Wilcoxon signed-rank tests, Kruskal-Wallis tests and multivariable
logistic regressions.
Results: Seventy four eyes of 74 patients were analyzed. Follow-up was at 12.0 to 15.7 weeks. Median difference of
BCVA (logMAR) between baseline and follow-up was 0.000 (−0.030, 0.175) in classic (p = 0.105), 0.000 (−1.15, 0.20) in
occult (p = 0.005), −0.200 (−1.20, 0.60) in cases with subretinal fluid (p = 0.207), 0.000 (-0.60, 0.30) in pigment
epithelial detachment (p = 0.813), and 0.050 (−0.40, 0.70) in Junius Kuhnt maculopathy (p = 0.344). BCVA increased ≥
0.2 logMAR in 4 (24 %) classic, 9 (47 %) occult, 6 (33 %) pigment epithelial detachment, 6 (55 %) subretinal fluid,
in 29 (39 %) eyes regardless of the lesion type, and reached a BCVA ≥ 0.05 in 7 (9 %) of those with a baseline
BCVA <0.05.
Conclusions: Results indicate that in patients with ARMD and a BCVA lower 0.05, intravitreal treatment may
improve visual acuity, most probably in cases with occult lesions.
Background
Age-related macular degeneration (ARMD) has become
one of the most threatening ophthalmologic diseases in
patients older than 50 years from developed countries
such as the United States or central Europe [1]. Stand-
ard treatment of exudative ARMD is repeat intravitreal
injection of anti-vascular endothelial growth factor
(VEGF) antibody, ranibizumab, aflibercept, or pegabta-
nib, which are legally accepted but expensive. Because
of increased age of the general population, insurance
companies are increasingly less likely to pay for treat-
ment for all patients [2]. Therefore, a few years ago,
insurance companies requested a minimal best cor-
rected visual acuity of ≥ 0.05 to financially cover ARMD
treatment with photodynamic therapy in Germany.
Actually, the recommendation of professional ophthal-
mological associations in Germany (Deutsche Ophthal-
mologische Gesellschaft, Retinologische Gesellschaft,
Berufsverband der Deutschen Augenärzte) to treat ex-
udative ARMD are not exclusively reduced to the
BCVA, but a BCVA of ≥ 0.05 is still a landmark, and
evidence based scientific investigations reporting about
such patients with low vision are missing. In other
countries the costs of these treatments is an issue, too
[3, 4]. Specifically, in these cases, intravitreal use of
bevacizumab, which costs much less, about one twenty-
fifth of ranibizumab, is a reasonable but off-label op-
tion. Several prospective controlled studies analyzing
BCVA development following intravitreal injection of
bevacizumab or ranibizumab have already been pub-
lished [5, 7–9]. However, unfortunately these studies do
not analyze treatment results in patients with BCVA
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lower than 0.05, probably because such inclusion crite-
rias, a minimal BCVA of 0.05 or 0.0625, have been
comparatively adapted since the beginning of photo-
dynamic treatment with verteporfin in 2003 in all major
studies, e.g. TAP, VIP, FOCUS, ANCHOR, MARINA,
PIER, or IVAN [10–16].
The primary aim of our analysis was to investigate
whether intravitreal treatment in exudative ARMD and
BCVA ≤ 0.05 had improved visual acuity in our patients.
Methods
This is a retrospective analysis of patients suffering
from exudative ARMD with BCVA ≤ 0.05 at baseline,
who received intravitreal injections of bevacizumab,
ranibizumab, triamcinolone, or in combination at our
University hospital. Following detailed information
about scientifically established pros and cons, includ-
ing side effects, e.g. possible secondary glaucoma or
cataract using triamcinolone, treatment regimen were
choosen depending on the patients’ economic possibil-
ities and final options. Treatment regimen did not fol-
low a strict rule. The patients were fully informed
about the experimental character of the treatments
and had given written informed consent.
Analyses adhered to the Declaration of Helsinki, and,
due to its retrospective character, an approval of the
study protocol was not necessary by the Ethics commit-
tee of the Medical Association of Westphalia-Lippe and
of the medical faculty of the Westphalian Wilhelms-
University, Muenster, Germany.
Retrospective analysis parameters were age and gender
of the patients, the type of exudative ARMD and best
corrected visual acuity (BCVA) tested with Snellen let-
ters at a distance of 5 meters and for VAs lower than
0.05 at 1 meter. BCVA had always been documented at
baseline and at follow-up, as well as the intravitreal drug
given, its application frequency, and dose. Inclusion cri-
teria were age ≥ 50 years and diagnosis of exudative
ARMD with a BCVA ≤ 0.05. Counting fingers was set at
0.013, and hand motion at 0.005 [15, 16]. A gain of ≥ 1
Snellen line was defined as an improvement in BCVA,
and a loss of ≤ 1 Snellen line as a decrease in BCVA.
Additionally, we evaluated the change in VA of 0.2 dif-
ference in logMAR which generally indicates two line
difference in ETDRS chart.
Exclusion criteria were excentric vision, a history of vi-
trectomy, any treatment with bevacizumab, pegabtanib,
or ranibizumab within the last six months, any intravit-
real application of triamcinolone within the last twelve
months, or a follow-up of less than 12 weeks.
The following groups were analyzed for BCVA:
After injection of bevacizumab, triamcinolone, ranibi-
zumab or in combination,
1. regardless of the subtype of choroidal neovascular
membrane (CNV),
2. according to the subtype of CNV (classic or occult),
3. patients without possible CNV classification
presenting subretinal fluids,
4. patients without possible CNV classification
presenting also pigment epithelial detachment,
5. patients without CNV classification presenting
macular scars and hemorrhages, defined as
Junius-Kuhnt maculopathy.
Statistical analyses were performed using IBM SPSS®
Statistics 22 for Windows (IBM Corporation, Somers,
NY, USA). Inferential statistics were intended to be ex-
ploratory instead of confirmatory, and were interpreted
accordingly, meaning that p-values were only used to
generate new hypotheses. Thus, neither a global signifi-
cance level nor local levels were determined, and no ad-
justment for multiplicity was made. P-values represent a
metric measure of evidence against the respective null
hypothesis, and were considered as statistically notice-
able if p ≤ 0.05.
Standard univariate statistical analyses were used to
describe demographical and clinical parameters. Cat-
egorical variables are shown as absolute and relative
frequencies. Continuous variables, which were assumed
to be normally distributed, are presented as mean ±
standard deviation. Non-normally distributed metric
variables are reported as median (minimum; maximum).
Comparisons of BCVA changes between baseline and fol-
low-up were conducted using exact nonparametric
Wilcoxon signed-rank tests. Changes were calculated by
subtracting baseline BCVA from follow-up-BCVA. Com-
parisons of BCVA between groups of different lesion
subtypes were conducted using Kruskal-Wallis test.
Additionally, BCVA (decimal acuity) was translated to
logMAR and analyzed using the same methods.
A multivariable logistic regression was calculated to
detect possible influences on the binary target param-
eter improvement of BCVA in decimal acuity (BCVA ≥
0.05 at follow-up). Independent parameters were age in
years, gender, and lesion type (classic lesion, occult le-
sion, subretinal fluids, pigment epithelial detachment,
Junius-Kuhnt maculopathy).
Results
Because of the inclusion and exclusion criteria, the
follow-up of 74 eyes from 74 patients with ARMD
could be analyzed. The mean age of these patients was
81.9 years (median 83.5, range 58–96 years), with 47
eyes from female and 27 from male patients. Follow-up
was at 12.0 to 15.7 weeks following intravitreal treat-
ments. CNV could be classified in 36 cases (Table 1),
17 of which were classic, 19 occult. In 38 eyes CNV
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could not be definitely classified anymore and edemas,
i.e. subretinal fluids were observed (n = 11), pigment
epithelial detachments (n = 9), macular hemorrhages
(n = 4), or typical Junius-Kuhnt maculopathy (n = 8).
Analysis of BCVA following injections of bevacizumab,
triamcinolone, in combination, or ranibizumab regardless
of the subtype of CNV, i.e. including classic, occult and
mixed forms
Intravitreal injections with either bevacizumab or triam-
cinolone were performed in 56 patients’ eyes. When
bevacizumab was used (n = 24), BCVA increased in
eleven patients (with eleven patients having an increase
of ≥ 0.2 logMAR), remained stable in seven patients, and
decreased in six patients.
When triamcinolone was used (n = 32), BCVA in-
creased in thirteen, remained stable in fifteen, and de-
creased in four patients (with eight patients having an
increase of ≥ 0.2 logMAR).
Regardless of the subtype of CNV (Table 1), the me-
dian difference in BCVA between posttherapy and base-
line was 0.000 (−0.040; 0.650, p < 0.001) in decimal








Number of eyes (n) 74 17 19 11 9 8
Gender (n): male/female 27/47 10/7 6/13 3/8 2/7 3/5
Patient age in years:
Mean 81.9 79.5 80.6 85.9 83.7 81.9
Standard deviation 7.6 8.9 8.1 5.5 4.2 5.9
Median 83.5 83.0 83.0 85.0 84.0 84.0
Minimum 58.0 58.0 59.0 77.0 76.0 70.0
Maximum 96.0 91.0 90.0 96.0 91.0 87.0
BCVA at baseline: decimal logMAR decimal logMAR decimal logMAR decimal logMAR decimal logMAR decimal logMAR
Mean 0.042 1.42 0.039 1.46 0.047 1.34 0.040 1.44 0.042 1.41 0.035 1.54
Standard deviation 0.130 0.22 0.015 0.26 0.009 0.14 0.014 0.21 0.014 0.21 0.017 0.34
Median 0.050 1.30 0.050 1.30 0.050 1.30 0.050 1.30 0.050 1.30 0.040 1.40
Minimum 0.005 1.30 0.005 1.30 0.013 1.30 0.013 1.30 0.013 1.30 0.005 1.30
Maximum 0.050 2.30 0.050 2.30 0.050 1.90 0.050 1.90 0.050 1.90 0.050 2.30
BCVA at follow-up:
Mean 0.082 1.27 0.065 1.33 0.138 1.04 0.077 1.26 0.061 1.36 0.029 1.69
Standard deviation 0.097 0.40 0.057 0.38 0.158 0.38 0.080 0.38 0.058 0.36 0.020 0.44
Median 0.050 1.30 0.050 1.30 0.050 1.30 0.050 1.30 0.050 1.30 0.030 1.55
Minimum 0.005 0.15 0.005 0.70 0.025 0.15 0.013 0.50 0.013 0.70 0.005 1.30




Mean 0.040 −0.15 0.026 −0.13 0.091 −0.30 0.038 −0.17 0.019 −0.06 −0.006 0.15
Standard deviation 0.096 0.36 0.057 0.31 0.157 0.40 0.086 0.28 0.054 0.37 0.012 0.19
Median 0.000 0.00 0.000 0.00 0.000 0.00 0.015 −0.20 0.000 0.00 −0.005 0.05
Minimum −0.040 −1.20 −0.030 −0.90 −0.015 −1.15 −0.037 −1.20 −0.025 −0.60 −0.020 −0.40
Maximum 0.650 0.70 0.175 0.40 0.650 0.20 0.028 0.60 0.150 0.30 0.010 0.70
Cases (n/%) of BCVA < 0.05
at baseline and > 0.05 at
final visit
7/9 % 2/12 % 1/5 % 2/18 % 0/0 % 1/13 %
Cases (n/%) with a decrease
of BCVA of > 0.2 logMAR
29/23 % 4/24 % 9/47 % 6/55 % 3/33 % 1/13 %
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acuity and 0.00 (−1.20; 0.70, p = 0.001) in logMAR . In
seven patients, BCVA in Snellen letters exceeded 0.05 at
final visit, though it had been less than 0.05 at baseline.
Analysis of BCVA according to the subtype of CNV
a) Classic CNV (n = 17):
If patients received bevacizumab, triamcinolone, a
combination, or ranibizumab, BCVA increased in
seven, remained stable in eight, and decreased in
two cases. The median differences between
posttherapy and baseline in BCVA were 0.000
(−0.030; 0.175, p = 0.074) in Snellen letters and 0.00
(−0.90; 0.40, p = 0.105) in logMAR. Two patients
exceeded 0.05 BCVA (decimal acuity) posttherapy,
and four patients (24 %) had an increase of ≥ 0.2
logMAR. If triamcinolone was injected once (n = 11),
BCVA improved in five and remained stable in four
cases (Fig. 1a). Two patients had an increase
of ≥ 0.2 logMAR.
b) Occult CNV (n = 19):
In patients with occult CNV and intravitreal
injection of bevacizumab, triamcinolone, or in
combination, or ranibizumab, BCVA (Snellen letters)
improved in nine cases (all of which exceeded a
BCVA (Snellen letters) of 0.05,
and nine increased ≥ 0.2 logMAR, (47.4 %)),
remained stable in eight cases, and decreased
in two cases (Fig. 1b).
Following injection of bevacizumab (n = 4), BCVA
remained stable in two patients, and increased in two pa-
tients. Following injection of triamcinolone (n = 12),
BCVA increased in five cases, all of whom had an increase
of ≥ 0.2 logMAR , remained stable in six and decreased in
one case. The median differences of BCVA in decimal
acuity 0.000 (−0.015; 0.650) and logMAR 0.00 (−1.15;
0.20) were statistically significant (p = 0.005, p = 0.005).
One patient who had a visual acuity of < 0.05 at baseline
exceeded 0.05 at final visit (Table 1).
Analysis of BCVA in patients with late stage ARMD and
subfoveal fluids
Because of the late stage of ARMD, CNV subtype could
not be definitely classified any more.
BCVA decreased in three eyes, remained stable in
two, and improved in six cases, all of these with an im-
provement ≥ 0.2 logMAR (55 %) following intravitreal
injection (single or multiple injections of bevacizumab,
triamcinolone, combination, or ranibizumab). In two
eyes, BCVA reached or exceeded 0.05 though it had
been lower than 0.05 at baseline (Fig. 1c). The median
differences between final visit and baseline of BCVA in
Snellen letters 0.015 (-0.037; 0.280) and logMAR −0.20
(−1.20; 0.60) were not statistically noticeable in patients
with late stage ARMD and subretinal fluids (p = 0.098;
p = 0.207). Nevertheless, increases in BCVA during
follow-up were observed most often in these patients
(Fig. 2).
Analysis of BCVA in patients without definite CNV
classification presenting pigment epithelial detachment
Similar to patients with subretinal fluids, it was not
possible any more to define CNV subtype. BCVA in-
creased in three eyes. In no case BCVA exceeded 0.05,
if it had been less at baseline. BCVA remained stable
in four cases and decreased in two cases (Fig. 3a). The
median differences between posttherapy and baseline
in decimal acuity (0.00; −0.025; 0.150, Table 1) and in
logMAR (0.00; −0.600; 0.30) were not noticeable
(p = 0.625; p = 0.813).
Analysis of BCVA in patients with Junius Kuhnt
maculopathie including subretinal foveal scars
Due to subretinal hemorrhages, and scars, it was not
possible to define CNV subtype any more. BCVA in-
creased in two patients (one with an increase of ≥ 0.2
logMAR), remained stable in two patients and de-
creased in four patients (Fig. 2). The median differ-
ences in BCVA Snellen letters and logMAR between
posttherapy and baseline were −0.005 (−0.020; 0.010;
p = 0.188) and 0.05 (−0.40; 0.70; p = 0.344) respectively
(Table 1, Fig. 3b).
Descriptive statistics showed a BCVA increase of 41 %
in patients with classic lesions, 47 % (occult), 33 % (pig-
ment epithelial detachment), 55 % (subretinal fluids),
and in 46 % regardless of the lesion type. In 29 patients
(39 %) an increase of ≥ 0.2 logMAR was observed, and in
7 (27 %) patients with baseline BCVA < 0.05, BCVA
reached or exceeded 0.05.
The difference in BCVA development between dif-
ferent lesion types (classic, occult, late stage ARMD
with subretinal fluids, pigment epithelial detachment,
or foveal scar/Junius-Kuhnt maculopathy) was statis-
tically not noticeable (decimal acuity p = 0.169; log-
MAR p = 0.190). Multivariable analysis using logistic
regression showed no noticeable influence of the
parameters gender, age and lesion type on the
improvement of BCVA.
Discussion
In practice, many patients consult their ophthalmolo-
gist when their BCVA has already decreased to less
than 0.05. At this time it is difficult to recommend a
definite procedure because it may not be clear whether
such therapy is efficient in these advanced cases, due to
the very little information that is actually known [19].
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Nevertheless, the Eyetech Study Group reported from
their phase 1A study of 5 of 6 patients with a baseline BCVA
of <0.05 (mean 0.025) which then increased to a mean of
0.036 on day 84 following treatment with pegabtanib [20].
In their phase II study, they also presented results of 3
patients with a baseline BCVA <0.05 (mean 0.035) which all
increased following treatment to a mean of 0.1 [21].
But in both studies, case numbers were too small and
lesion types have not been classified to allow specific
characterization.
Fig. 1 Development of BCVA in patients with exsudative ARMD and (a) classic subtype, (b) occult subtype, and (c) in cases with subfoveal fluids
without subtype differentiation. Grey area defines cases with visual acuity that have increased and exceeded 0.05 decimal acuity (Snellen letters,
left side) or gone below 1.3 logMAR (right side) during follow-up. Due to equal values (ties), a random offset was added to these values to
enhance visibility
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Fig. 2 Development of BCVA in different ARMD subtypes during follow-up
Fig. 3 Development of BCVA in patients with exudative ARMD and (a) pigment epithelial detachment, and (b) Junius-Kuhnt maculopathy. Grey
area defines cases with visual acuity that have increased and exceeded 0.05 decimal acuity (Snellen letters, left side) or gone below 1.3 logMAR
(right side) during follow-up. Due to equal values (ties), a random offset was added to these values to enhance visibility
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Sørensen and Kemp, instead, analyzed retrospectively
33 patients suffering from age-related macular degener-
ation which presented an increase of mean BCVA from
logMAR 1.3 (range 1.1–2) to 1.0 (range 0.3–2) following
treatment with intravitreal ranibizumab [19]. Unfortu-
nately, the authors did not specify the lesion subtypes.
The Comparisons of Age-Related Macular Degener-
ation Treatments Trials (CATT) Research Group has
published a two-year study, comparing the intravitreal
efficacy of ranibizumab with bevacizumab in exudative
ARMD with equivalent effects on BCVA. However, the
study also focused only on patients with a minimal
BCVA of 0.0625 [5], and Biswas and coworkers who ob-
served equal effects regarding the efficiencies of bevaci-
zumab and ranibizumab in the treatment of neovascular
ARMD did not include low vison patients neither [6].
In a retrospective analysis of the treatment of 48 eyes
of 47 patients, which presented a baseline BCVA be-
tween 20/150 till hand movements (logMAR 1.34 ±
0.25), Ehrlich and coworker described a BCVA increase
to 20/50 till countingfingers (logMAR 1.2 ± 0.42) with a
BCVA improved by ≥3 lines in 25 % following intravit-
real application of bevacizumab [22].
In our retrospective investigation, BCVA exceeded
0.05 in 9 % of patients with baseline BCVA <0.05 irre-
spective of the subtype of exudative ARMD. And we
observed a BCVA increase in nearly one third of all pa-
tients irrespective of the subtype of exudative ARMD.
BCVA increased most often in occult lesions and in
those cases, where subtypes could not be classified any
more, but presented subretinal fluids. We cannot prove
but presume that these maculopathies have been origi-
nated from former occult lesions, as well, since well de-
marcated lesions were not seen.
Though Jonas et al. and Tao & Jonas did not observe
a correlation between the lesion subtype and the devel-
opment of BCVA in ARMD, our investigation supports
the hypothesis that in patients with exudative ARMD
with BCVA < 0.05, retinas with occult CNV benefit
more than those with classic lesions [23, 24]. Patients
with Junius-Kuhnt maculopathy presented most often a
decrease in BCVA, and mean BCVA was comparably
lowest during follow-up which is reasonable, because
these maculopathies often present foveally located
scars. Due to small sample size, treatment efficiency of
eyes with mixed CNV, or macular hemorrhage were not
analyzed.
The usefulness of our study is limited by its retro-
spective nature, a relatively small number of patients,
the heterogeneity of intravitreally applied drugs and fre-
quencies, the partial difficulty in diagnosing a lesion
subtype, and the fact that many patients were not able
to pay and stopped repetitive treatment, even when
intravitral medication improved BCVA. As we did not
have any control group, it was not possible to exclude a
placebo-like effect.
Conclusions
Similar to Galbinur et al. who retrospectively analyzed
patients with wet ARMD and a BCVA of 0.1 or worse
[25], our results suggest that for patients with ARMD
and a BCVA < 0.05, intravitreal treatment may improve
visual acuity, specifically in cases with occult lesions. We
therefore suggest to specify such outcomes in late stages
of ARMD also with the use of an EDTRS or a Radner
chart [26, 27], including investigation of contrast or glare
sensitivity and color vision, or adaptation to darkness
[17] which could emphasize such treatment benefits. As
the use of intravitreal steroids have been reported to be
only helpful in the short-term follow-up [28], such inves-
tigations should primarily focus on Anti-VEGF agents to
characterize the most useful intravitreal drug and the
baseline threshold of BCVA for which treatment is still
significantly helpful.
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